Literature DB >> 11154704

Reciprocal regulatory interaction between human herpesvirus 8 and human immunodeficiency virus type 1.

L M Huang1, M F Chao, M Y Chen, Y P Chiang, C Y Chuang, C Y Lee.   

Abstract

Human herpesvirus 8 (HHV8) is the primary viral etiologic agent in Kaposi's sarcoma (KS). However, individuals dually infected with both HHV8 and human immunodeficiency virus type 1 (HIV-1) show an enhanced prevalence of KS when compared with those singularly infected with HHV8. Host immune suppression conferred by HIV infection cannot wholly explain this increased presentation of KS. To better understand how HHV8 and HIV-1 might interact directly in the pathogenesis of KS, we queried for potential regulatory interactions between the two viruses. Here, we report that HHV8 and HIV-1 reciprocally up-regulate the gene expression of each other. We found that the KIE2 immediate-early gene product of HHV8 interacted synergistically with Tat in activating expression from the HIV-1 long terminal repeat. On the other hand, HIV-1 encoded Tat and Vpr proteins increased intracellular HHV8-specific expression. These results provide molecular insights correlating coinfection with HHV8 and HIV-1 with an unusually high incidence of KS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11154704     DOI: 10.1074/jbc.M011314200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  Inhibition of gammaherpesvirus replication by RNA interference.

Authors:  Qingmei Jia; Ren Sun
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

Review 2.  Molecular biology of KSHV in relation to AIDS-associated oncogenesis.

Authors:  Whitney Greene; Kurt Kuhne; Fengchun Ye; Jiguo Chen; Fuchun Zhou; Xiufen Lei; Shou-Jiang Gao
Journal:  Cancer Treat Res       Date:  2007

Review 3.  Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis.

Authors:  Qiliang Cai; Suhbash C Verma; Jie Lu; Erle S Robertson
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

4.  Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma.

Authors:  R Tedeschi; M Enbom; E Bidoli; A Linde; P De Paoli; J Dillner
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

5.  Kaposi's sarcoma-associated herpesvirus ORF45 mediates transcriptional activation of the HIV-1 long terminal repeat via RSK2.

Authors:  John Karijolich; Yang Zhao; Bret Peterson; Qiang Zhou; Britt Glaunsinger
Journal:  J Virol       Date:  2014-04-09       Impact factor: 5.103

6.  Seroprevalence and determinants of human herpes virus 8 infection in adult Nigerians with and without HIV-1 infection.

Authors:  D Ogoina; G Onyemelukwe; B O Musa; A Babadoko
Journal:  Afr Health Sci       Date:  2011-06       Impact factor: 0.927

7.  Inhibition of Kaposi's sarcoma-associated herpesvirus lytic replication by HIV-1 Nef and cellular microRNA hsa-miR-1258.

Authors:  Qin Yan; Xinting Ma; Chenyou Shen; Xu Cao; Ninghan Feng; Di Qin; Yi Zeng; Jianzhong Zhu; Shou-Jiang Gao; Chun Lu
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

8.  Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response.

Authors:  Huong Q Nguyen; Amalia S Magaret; Mari M Kitahata; Stephen E Van Rompaey; Anna Wald; Corey Casper
Journal:  AIDS       Date:  2008-05-11       Impact factor: 4.177

9.  Antagonism of host antiviral responses by Kaposi's sarcoma-associated herpesvirus tegument protein ORF45.

Authors:  Fan Xiu Zhu; Narayanan Sathish; Yan Yuan
Journal:  PLoS One       Date:  2010-05-11       Impact factor: 3.240

10.  Contrasting roles for TLR ligands in HIV-1 pathogenesis.

Authors:  Beda Brichacek; Christophe Vanpouille; Yana Kiselyeva; Angelique Biancotto; Melanie Merbah; Ivan Hirsch; Andrea Lisco; Jean Charles Grivel; Leonid Margolis
Journal:  PLoS One       Date:  2010-09-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.